Press release PEP-Therapy and Institut Curie Announce First Patients Dosedin Phase Ib Clinical Trial Evaluating PEP-010in Ovarian and Pancreatic Cancers Paris (France), April 25, 2024 “ PEP-Therapy,...
PEP-Therapy, a clinical-stage biotechnology company developing cell penetrating peptides as targeted therapies in oncology, and Institut Curie, France's leading cancer center, announce that the first patients have been dosed in a phase Ia/b multicenter clinical trial evaluating PEP-Therapy's lead candidate, PEP-010. In this first-in-human trial, PEP-010 is being administered in patients with advanced solid tumors.
PEP-Therapy extends Series-A financing
Market Place
Share
Share
